Iatrogenic hyperkalaemia - Points to consider in diagnosis and management

Nephrology Dialysis Transplantation

Volumn 13, Issue 9, 1998, Pages 2402-2406

  Siamopoulos, Kostas C ^a   Elisaf, Moses ^a   Katopodis, Kostas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPERKALEMIA; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; DIURETICS; FEMALE; HUMANS; HYPERKALEMIA; IATROGENIC DISEASE; MALE; TRIMETHOPRIM;

EID: 0031667068     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.9.2402     Document Type: Article

References (66)

1. Brown RS. Extrarenal potassium homeostasis. Kidney Int 1986; 30: 116 127
2. Stanton BA. Renal potassium transport: Morphological and functional adaptations. Am J Physiol 1989; 257: R989-R997
3. Wright FS. Renal potassium handling. Semin Nephrol 1987; 7: 174-184
4. Rabclink TJ. Koomans HA, Hene' RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38: 942-947
5. Rose BD. Hyperkalemia In: Rose BD, ed. Clinical Physiology of Acid Base and Electrolyte Disorders. 4th edn. McGraw Hill, New York, 1994; 823-862
6. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine 1985; 64: 357-370
7. DeVita MV, Han H, Chan R, Zabetakis PM, Gleim GW, Michelis MF. Drug use and the elderly in relation to changing etiologies of hyperkalemia. Geriatr Nephrol Urol 1991; 1: 41-45
8. Rimmer JM, Horm JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med 1987; 147: 867-869
9. Michelis MF. Hyperkalemia in the elderly. Am J Kidney Dis 1990; 16; 296-299
10. Hegstad R, Brown RD, Jiang N-S et al. Aging and aldosterone. Am J Med 1983; 74: 442-448
11. Mulkerrin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol 1995; 6: 1459-1462
12. DuBose TD. Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. Kidney Int 1997; 51: 591-602
13. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124: 316-320
14. Elisaf M, Terrovitou Ch, Tomos P, Siamopoulos KC. Severe hyperkalaemia after co-trimoxazole administration in a patient with hyporeninaemic hypoaldosteronism. Nephrol Dial Transplant 1997; 12: 1254-1255
15. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17: 118-134
16. Williams GH. Hyporeninemic hypoaldostcronism. N Engl J Med 1986; 314: 1041-1042
17. Choi MJ, Fernandez PC, Patnaik A et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328: 703-706
18. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Am Intern Med 1993; 119: 296-301
19. Schreiber M, Schlanger LE, Chen C-B et al. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996; 49: 82-87
20. Schreiber M, Halperin ML. Urea excretion rate as a contributor to trimethoprim-induced hyperkalemia. Ann Intern Med 1994; 120: 166 167
21. Reiser IW, Chou S-Y, Brown MI, Porush JG. Reversal of trimethoprim-induced antikaliuresis. Kidney Int 1996; 50: 2063-2069
22. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996; 49: 314-326
23. Prendergast BD, George CF. Drug-induced rhabdomyolysis mechanisms and management. Postgrad Med J 1993; 69: 333-336
24. Terrovitou CT, Milionis HJ, Elisaf MS. Acute rhabdomyolysis after bezafibrate re-exposure. Nephron (in press)
25. Demedts W, Desager Z, Belpaire F, Rinqoir S, Lameire N. Life threatening hyperkalemia associated with clofibrate-induced myopathy in a CAPD patient. Perit Dial Bull 1983; 3: 15-16
26. Textror SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73:719 725
27. Doman K, Perlmutter JA, Muhammedi M et al. Life-threatening hyperkalemia associated with captopril administration. South Med J 1993; 86: 1269-1272
28. Gorriz JL, Garcia-Ramos JL, Pallardo LM. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995; 10: 2371 2372
29. Chan MK. Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56-61
30. Van Puijenbroek EP, DuBuf-Vereijken PWG, Spooren PFMJ, Van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-404
31. Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient, Nephron 1996; 73: 736
32. Bedani PL, Perini L, Gilli P. Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 1994; 68: 512-513
33. Gupta P, Franco-Saenz R, Mulrow PJ. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin, and potassium stimulated aldosterone secretion. Hypertension 1995; 25: 443-448
34. Pratt J. Role of angiotensin II in potassium mediated aldosterone secretion in the dog. J Clin Invest 1982; 70: 667-672
35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 1984; 144: 1947 1953
36. Grossman A, Eckland D, Price P et al. Captopril: reversible renal failure with severe hyperkalemia. Lancet 1980; 1: 712
37. Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting cnzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 1986; 57: 347 370
38. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation. Arch Intern Med 1984; 144: 2371-2372
39. Sterns RH, Spital A. Disorders of internal potassium balance. Semin Nephrol 1987; 7: 206-222
40. Bauer JH, Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 1983; 14: 927-931
41. Lim M, Linton RAF, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 12: 591
42. Bethune DW, McKay R. Paradoxical changes in serumpotassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet 1978; 12: 380-381
43. Lowenthal DT, Affrime MB, Rosenthal L, Gould AB, Borruso J, Falkner B. Dynamic and biochemical responses to single and repeated doses of clonidine during dynamic physical activity. Clin Pharmacol Ther 1982; 32: 18-24
44. Rosenthal LS, Lowenthal DT, Affrime MB, Falkner B, Gould AB. The renin-aldosterone-potassium response to methyldopa during dynamic physical activity. Clin Pharmacol Ther 1982; 31: 264-265
45. Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37: 773-798
46. Tan SY, Shapiro R, Franco R et al. Indomethacin induced prostaglandin inhibition with hyperkalemia: A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979; 90: 783-785
47. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine 1984; 63:165-181
48. Zimran A, Krämer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Lancet 1985; 291: 107-108
49. Phelps KR, Oh MS, Carroll HJ. Heparin-induced hyperkalemia. Report of a case. Nephron 1980; 25: 254
50. Sherman RA, Ruddy MC. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 1986; 6: 165
51. O'Kelly R, Magee F, McKenna TF. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 1983; 56: 108-112
52. Edes TE, Sunderrajan EV. Heparin-induced hyperkalemia. Arch Intern Med 1985; 145: 1070-1072
53. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppresion and hyperkalemia. Am J Med 1995; 98: 575 586
54. Gonzalez-Martin G, Diaz-Molinas MS, Martinez AM et al. Heparin-induced hyperkalemia: a prospective study. Int J Clin Pharmacol Ther Toxicol 1991; 29: 446-450
55. Durand D, Ader J-L, Rey J-P et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int 1988; 34[Suppl 25]: S196-S197
56. Amonipillai I, Wang Y, Horton R. Tumor necrosis factor and interleukin-1 may regulate renin secretion. Endocrinology 1990; 126: 273-278
57. Canova CR, Fischler MP, Reinhart WH. Effect of low-molecular-weight heparin on serum potassium. Lancet 1997; 349: 1447-1448
58. Wiggam MI, Beringer TRO. Effect of low-molecular-weight heparin on serum concentrations of potassium. Lancet 1997; 350: 292-293
59. Kleyman TR, Robers C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122: 103-106
60. Kalin M, Poretsky L, Seres DJ, Zumoff B. Hypereninemic hypoaldosteronism associated with AIDS. Am J Med 1987; 82: 1035-1038
61. Kamel KS, Ethier JH, Quaggin S et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1991; 2: 1279-1284
62. Bantle JP, Nath KA, Sutherland ER, Najarian JS, Ferris TF. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med 1985; 145: 505-508
63. Smith TW. Digitalis: Mechanisms of action and clinical use. N Engl J Med 1988; 318: 358-365
64. Lown B, Black A, Moore FD. Digitalis, electrolytes and the surgical patient. Am J Cardiol 1960; 6: 309-311
65. Asplund J, Edhag O, Mogensen L et al. Four cases of massive digitalis poisoning. Acta Med Scand 1971; 189: 293-297
66. Reza MJ, Kovick RB, Shine KI, Pearce ML. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291: 777-778